We draw inspiration from Tarlatamab's, a recently approved DLL3-CD3 BiTE that enables multiple mechanism of protection by targeting the atypical DLL3 Notch ligand whose overexpression promotes the growth of small cell lung cancer and also enhances their migratory and invasive capacity 37. This evidence concerns the gene DLL3 and small cell lung carcinoma.